S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
WARNING: Do You Invest with these Banks (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
WARNING: Do You Invest with these Banks (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
3 Stocks Set to Lead the Nasdaq Bull Market
126% Average Gains While Stocks Crash (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
WARNING: Do You Invest with these Banks (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
WARNING: Do You Invest with these Banks (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
3 Stocks Set to Lead the Nasdaq Bull Market
126% Average Gains While Stocks Crash (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
WARNING: Do You Invest with these Banks (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
WARNING: Do You Invest with these Banks (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
3 Stocks Set to Lead the Nasdaq Bull Market
126% Average Gains While Stocks Crash (Ad)pixel
S&P 500   4,297.14
DOW   33,912.44
QQQ   333.06
The Five Hottest Calls From The Q2 Earnings Season 
WARNING: Do You Invest with these Banks (Ad)pixel
Buffett's firm buys more Apple, Amazon while betting on oil
Norway hits export record amid soaring gas prices
Stocks end higher on Wall Street; economic worries hit oil
WARNING: Do You Invest with these Banks (Ad)pixel
Myanmar executions revive pressure for more sanctions
Stocks higher on Wall Street; economic worries hit oil price
3 Stocks Set to Lead the Nasdaq Bull Market
126% Average Gains While Stocks Crash (Ad)pixel

GSK - GSK Stock Forecast, Price & News

$34.95
-1.08 (-3.00%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$34.42
$35.23
50-Day Range
$34.95
$44.25
52-Week Range
$34.42
$46.97
Volume
15.39 million shs
Average Volume
5.60 million shs
Market Capitalization
$71.08 billion
P/E Ratio
11.57
Dividend Yield
4.64%
Price Target
N/A

GSK MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.30% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.39mentions of GSK in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
5.25%
From $3.43 to $3.61 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

767th out of 1,125 stocks

Pharmaceutical Preparations Industry

387th out of 554 stocks

GSK stock logo

About GSK (NYSE:GSK) Stock

GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Lyell Immunopharma, Inc.; Novartis; Sanofi SA; Surface Oncology; Progentec Diagnostics, Inc.; Alector, Inc.; and CureVac AG., as well as strategic partnership with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK Trading Down 4.0 %

NYSE:GSK traded down $1.43 during trading hours on Monday, hitting $34.60. 312,133 shares of the company were exchanged, compared to its average volume of 5,540,508. The stock has a market capitalization of $70.37 billion, a price-to-earnings ratio of 11.93, a price-to-earnings-growth ratio of 1.29 and a beta of 0.46. The company has a current ratio of 1.43, a quick ratio of 1.31 and a debt-to-equity ratio of 0.83. GSK has a one year low of $34.50 and a one year high of $46.97. The company has a fifty day simple moving average of $41.97 and a 200 day simple moving average of $43.21.

GSK Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 6th. Stockholders of record on Friday, August 19th will be given a $0.383 dividend. The ex-dividend date of this dividend is Thursday, August 18th. This is a positive change from GSK's previous quarterly dividend of $0.35. This represents a $1.53 annualized dividend and a dividend yield of 4.43%. GSK's dividend payout ratio (DPR) is 55.30%.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. TheStreet raised GSK from a "c+" rating to an "a-" rating in a report on Friday, July 22nd. Citigroup reissued a "neutral" rating on shares of GSK in a report on Thursday, July 21st. Barclays raised their price objective on GSK from GBX 1,775 ($21.45) to GBX 1,800 ($21.75) in a report on Friday, April 29th. AlphaValue downgraded GSK to a "reduce" rating in a report on Tuesday, July 19th. Finally, JPMorgan Chase & Co. raised their price objective on GSK from GBX 1,740 ($21.02) to GBX 1,900 ($22.96) in a report on Thursday, April 28th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, one has given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Hold" and a consensus price target of $1,787.50.

Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Stock News Headlines

GSK (NYSE:GSK) Stock Rating Reaffirmed by Morgan Stanley
GSK plc (NYSE:GSK) Short Interest Update
GSK (NYSE:GSK) Rating Reiterated by Citigroup
GSK (NYSE:GSK) Price Target Cut to GBX 1,850
GSK (NYSE:GSK) Downgraded by AlphaValue to "Reduce"
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

GSK Company Calendar

Last Earnings
2/02/2021
Ex-Dividend for 7/1 Dividend
5/19/2022
Dividend Payable
7/01/2022
Today
8/16/2022
Ex-Dividend for 10/6 Dividend
8/18/2022
Dividend Payable
10/06/2022
Next Earnings (Estimated)
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
90,096
Year Founded
2000

Profitability

Net Income
$6.03 billion
Pretax Margin
16.84%

Debt

Sales & Book Value

Annual Sales
$46.91 billion
Cash Flow
$3.51 per share
Book Value
$13.62 per share

Miscellaneous

Outstanding Shares
2,033,677,000
Free Float
1,830,309,000
Market Cap
$71.08 billion
Optionable
Optionable
Beta
0.46

Social Links


Key Executives

  • Ms. Emma N. Walmsley (Age 52)
    CEO & Director
    Comp: $4.59M
  • Mr. Iain James Mackay (Age 60)
    CFO & Exec. Director
    Comp: $3.41M
  • Dr. Hal V. Barron F.A.C.C. (Age 59)
    M.D., Chief Scientific Officer, Pres of R&D and Director
    Comp: $6.16M
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Sr. VP & Group Gen. Counsel of Legal & Compliance
  • Ms. Sally Jackson
    Sr. VP of Global Communications & CEO Office
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. David Simon Redfern (Age 56)
    Chief Strategy Officer
  • Mr. Philip C. Thomson
    Pres of Global Affairs













GSK Stock - Frequently Asked Questions

Should I buy or sell GSK stock right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 1 sell rating, 7 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

How have GSK shares performed in 2022?

GSK's stock was trading at $44.10 at the beginning of the year. Since then, GSK shares have decreased by 20.7% and is now trading at $34.95.
View the best growth stocks for 2022 here
.

Are investors shorting GSK?

GSK saw a increase in short interest during the month of July. As of July 31st, there was short interest totaling 6,120,000 shares, an increase of 9.9% from the July 15th total of 5,570,000 shares. Based on an average daily volume of 4,690,000 shares, the short-interest ratio is currently 1.3 days. Currently, 0.3% of the shares of the stock are short sold.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, October 26th 2022.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) announced its quarterly earnings data on Tuesday, February, 2nd. The pharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by $0.02. The pharmaceutical company had revenue of $8.74 billion for the quarter, compared to analyst estimates of $8.71 billion. GSK had a trailing twelve-month return on equity of 27.84% and a net margin of 12.91%. The business's revenue was down 1.8% compared to the same quarter last year. During the same quarter last year, the business posted $0.39 EPS.
Read the conference call transcript
.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK announced a quarterly dividend on Wednesday, July 27th. Stockholders of record on Friday, August 19th will be paid a dividend of $0.383 per share on Thursday, October 6th. This represents a $1.53 annualized dividend and a yield of 4.38%. The ex-dividend date of this dividend is Thursday, August 18th. This is a boost from the stock's previous quarterly dividend of $0.35.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.67 per share and currently has a dividend yield of 4.64%. GSK has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer. The dividend payout ratio is 55.30%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 46.26% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What guidance has GSK issued on next quarter's earnings?

GSK issued an update on its FY 2022 earnings guidance on Thursday, August, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $49.73 billion-$50.67 billion, compared to the consensus revenue estimate of $38.72 billion.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

What is GSK's stock symbol?

GSK trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

Who are GSK's major shareholders?

GSK's stock is owned by many different retail and institutional investors. Top institutional investors include Dodge & Cox (3.65%), FMR LLC (0.87%), Renaissance Technologies LLC (0.49%), JTC Employer Solutions Trustee Ltd (0.43%), Equity Investment Corp (0.15%) and Bain Capital Public Equity Management II LLC (0.11%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is GSK's stock price today?

One share of GSK stock can currently be purchased for approximately $34.95.

How much money does GSK make?

GSK (NYSE:GSK) has a market capitalization of $71.08 billion and generates $46.91 billion in revenue each year. The pharmaceutical company earns $6.03 billion in net income (profit) each year or $3.02 on an earnings per share basis.

How many employees does GSK have?

The company employs 90,096 workers across the globe.

When was GSK founded?

GSK was founded in 2000.

How can I contact GSK?

GSK's mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The official website for the company is www.gsk.com. The pharmaceutical company can be reached via phone at 442080475000, via email at gsk.investor-relations@gsk.com, or via fax at 44-20-8047-7807.

This page (NYSE:GSK) was last updated on 8/16/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.